Revenue

6 Months Ended

Jun. 30, 2022

Disaggregation Of Revenue [Abstract]

Revenue

11. Revenue  

The following table provides information about disaggregated revenue by product mix and service (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Product revenue:
ANNOVERA	$	18,271	$	9,555	$	26,781	$	18,305
IMVEXXY		6,667		9,838		13,636		16,850
BIJUVA		2,654		2,156		5,214		4,601
Prescription vitamin		904		1,402		1,779		2,827
Product revenue, net		28,496		22,951		47,410		42,583
License and service		65		50		484		284
Total revenue, net	$	28,561	$	23,001	$	47,894	$	42,867

We have entered into a license and supply agreement (the “Knight License Agreement”), with Knight Therapeutics, Inc. (“Knight”) pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. We also have entered into a licensing and supply agreement (the “Theramex License Agreement”) with Theramex HQ UK Limited (“Theramex”) pursuant to which we granted Theramex an exclusive license to commercialize IMVEXXY and BIJUVA for human use outside of the U.S., except for Canada and Israel.

BIJUVA sales through the Theramex License Agreement started in the third quarter of 2021, and we recorded BIJUVA sales through the Theramex License Agreement of $0.3 million and $1.0 million for the three and six months ended June 30, 2022, respectively. As of June 30, 2022, no BIJUVA sales have been made through the Knight License Agreement, and no IMVEXXY sales have been made through either of the licensing agreements.